Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 24 of 24 publications.

Michaud K, Pope J, van de Laar M, Curtis JR, Kannowski C, Mitchell S, Bell J, Workman J, Paik J, Cardoso A, Taylor PC. A systematic literature review of residual symptoms and unmet need in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021 Nov;73(11):1606-16. doi: 10.1002/acr.24369

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer. 2019 Feb 8;2019:11-20. doi: 10.2147/LCTT.S179349

Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 2019 Feb;128(2019):74-90. doi: 10.1016/j.lungcan.2018.12.003

Burkard T, Huegle T, Layton JB, Glynn RJ, Bloechliger M, Frey N, Jick SS, Meier CR, Spoendlin J. The risk of incident osteoarthritis of the hand in statin initiators:a sequential cohort study. Arthritis Care Res (Hoboken). 2018 Dec;70(12):1795-805. doi: 10.1002/acr.23616

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018 Oct;124:310-6. doi: 10.1016/j.lungcan.2018.07.042.

Coates L, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK. Minimal disease activity among active psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-35. doi: 10.1002/acr.23537

Druce KL, Jones GT, Macfarlane GJ, Basu N. Examining changes in central and peripheral pain as mediates of fatigue improvement: results from the British society for rheumatology biologics register for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jul;68(7):922-6. doi: 10.1002/acr.22803

Du XL, Parikh RC, Lairson DR. Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007–2010 after the 2006 introduction of bevacizumab. Lung Cancer. 2015 Dec;90(3):442-50.

Davis KL, Goyal RK, Able SL, Brown J, Li L, Kaye JA. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer. 2015 Feb;87(2):176-85. doi: 10.1016/j.lungcan.2014.11.002

Poulos C, Hauber AB, González JM, Turpcu A. Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1008-15. doi: 10.1002/acr.22265

Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1073-84. doi: 10.1002/acr.22214

Luciano JV, Aguado J, Serrano-Blanco A, Calandre EP, Rodriguez-Lopez CM. Dimensionality, reliability, and validity of the revised fibromyalgia impact questionnaire in two Spanish samples. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1682-9.

Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1357-64. doi: 10.1002/acr.21709

Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease evidence from a United States managed care population. Hum Vacci. 2011 Apr 1;7(4):458-65.

Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vacci. 2011 Jan 1;7(1):96-101.

Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Sturmer T. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Care Res (Hoboken). 2008 Aug 15;59(8):1097-104.

Mease P, Arnold L, Crofford L, Williams D, Russell IJ, Humphrey L, Abetz L, Martin SA. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient delphi exercises. Arthritis Care Res (Hoboken). 2008 Jul;59(7):952-60.

Talmud PJ, Stephens JW, Hawe E, Demissie S, Cupples LA, Hurel SJ, Humphries SE, Ordovas JM. The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet. 2005;69(6):613-22.

Hawe E, Talmud PJ, Miller GJ, Humphries SE, Northwick Park Heart Study . Second Northwick Park Heart Study. Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study. Ann Hum Genet. 2003;67(Pt 2):97-106.

Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet. 2002;66(Pt 2):111-24.

Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy - Lung (FACT-L): analysis of ECOG 5592 data. Poster presented at the 7th Central European Lung Cancer Conference; June 2001. Prague, Czech Republic. [abstract] Lung Cancer. 2001 May; 32(Suppl 1):52.

Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Bonomi P, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy (lung) (FACT-L): analysis of ECOG 5592 data. Lung Cancer. 2001;373-6.

Dreyer NA, Loughlin JE, Rothman KJ. Epidemiologic safety surveillance of cellular telephones in the US. Radiat Prot Dosimetry. 1999 Jun;83(1):159-63.